Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Leukemia, Chronic Myeloid Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02389920
• Other study ID #: 2014-01-112
• Status: Not yet recruiting
• Phase: Phase 4
• First received: March 11, 2015
• Last updated: March 16, 2015
• Start date: April 2015
• Est. completion date: December 2018

Study information

• Verified date: March 2015
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

Describe the purpose of the study: This study aims to evaluate the improvement of Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Men and women = 19 years old

2. Performance status (ECOG) of 0, 1, or 2

3. Chronic phase or accelerated phase chronic myeloid leukemia being treated for more than two weeks, switch to nilotinib.

4. Appropriate target organ function defined as;

• Bilirubin < 1.5 X ULN- Liver function test, AST (SGOT) and ALT (SGPT) < 2.5 X ULN- Creatinine < 1.5 X ULN- Serum amylase and lipase = 1.5 X ULN- Alkaline phosphatase = 2.5 X ULN (only if not related to tumor)

5. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to the start of study drug administration.

6. Should have laboratory results as follows.

• Potassium = LLN- Magnesium = LLN- Phosphorus = LLN

7. Voluntary, signed and dated informed consent prior to any study procedures being performed

Exclusion Criteria:

1. Subjects with the T315I mutation

2. Mutation known to be associated with low sensitivity to nilotinib(e.g., Y253H, E255K, E255V, F359V),

3. Cardiac function abnormalities as follows are found.

• FEVI < 45% or less than lower limit of normal of each center on ECG

• QT interval cannot be measured on ECG

• Complete right bundle branch block

• Using a ventricular pacemaker

• Congenital long QT syndrome or family history of long QT syndrome

• Past or present clinically significant ventricular or atrial tachycardia

• Clinically significant bradycardia at rest (< 50 beats/min)

• Regardless of toxicity after Dasatinib intake, QTc > 480 msec (using the QTcF formula) at baseline ECG. If QTcF > 480 msec and electrolytes are not within the normal range, it is necessary to correct electrolytes and re-assess the patient's QTc. According to the result of QTc, the investigator makes a decision on the patient's enrollment.

• Myocardial infarction within 12 months prior to the start of the study

• Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension)

4. Cytopathologically confirmed central nervous system lumbar puncture (spinal tapping is not needed if it is not suspected of association with central nervous system)

5. Severe or uncontrolled disease (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection)

6. History of significant congenital or acquired, bleeding disorder unrelated to cancer

7. 25% or more of bone marrow has been treated with prior radiotherapy

8. Not recovered from prior surgery or having a major surgery within 4 weeks from Day -1 of the study

9. Treated with other investigational product within 30 days

10. History of noncompliance with medical treatment or unable to voluntarily provide the written signed and dated informed consent

11. Other primary cancer which is currently clinically significant and requires active treatment

12. Currently treated with a strong CYP3A4 inhibitor (e.g., erythromycin, ketoconazole, itraconazol, voriconazol, clarithromycin, telithromycin, ritonavir, mibefradil), and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list, refer to this link: http://medicine.iupui.edu/flockhart/table.htm.)

13. Gastrointestinal dysfunction or gastrointestinal disease that may significantly change the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass)

14. History of acute pancreatitis within the past 1 year or history of chronic pancreatitis

15. Acute or chronic uncontrolled liver, pancreas or severe renal disease unrelated to the disease

16. Currently treated with a drug which may prolong QT interval, and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list of products which prolong QT interval, refer to http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)

17. Pregnant women, breast-feeding women

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia, Chronic Myeloid
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Philadelphia Chromosome

Intervention

Drug:
• Nilotinib

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of improvement of Dasatinib-related adverse events		at 3 months of nilotinib treatment	No